ProMIS Neurosciences Announces New Peer-Reviewed Publication Showing Plasma pTau as a Predictive Early Endpoint in Alzheimer's trials, Supporting its Ongoing Phase 1b PRECISE-AD trial with PMN310
Cross-trial analysis supports plasma pTau as a potential early predictor of clinical benefit, reinforcing the biomarker-driven design of ProMIS' PRECISE-AD trial ProMIS on track to leverage new plasma pTau insights with planned Q2 2026 interim readout Cambrid
(Financial Post, 2025-12-01T12:35:17Z)